Celgene negotiates drug discovery and license agreement with PTC Therapeutics
Clients Celgene Corporation
Jones Day negotiated a $20 million drug discovery and license agreement between Celgene Corporation and PTC Therapeutics. Under the terms of the agreement, Celgene received exclusive development rights to orally bioavailable small molecules for two undisclosed oncology targets and was granted access to the Gene Expression Modulation by Small Molecules (GEMS) screening technology. The transaction also included a stock purchase agreement.